SLC5A2 and hydrops fetalis: The key mechanism by which SGLT2 inhibitors modifies HF risk is that they bind the sodium binding sites of sodium-hydrogen exchanger (NHE-1) and attenuate the cytosolic sodium and calcium, improving calcium concentration in the sarcoplasmic reticulum (Uthman et al., 2018).